QIAGEN Reports First Quarter 2012 Results
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
. - Net sales rise 12% (+13% CER) to $296.4 million, adjusted operating income advances 14% to $80.3 million and adjust…
. - Both products receive 510(k) clearance for in vitro diagnostic use in the U.S. - Rotor-Gene Q MDx platform offers…
. - Significant progress on strategic initiatives to drive growth and innovation: - Driving platform success: More…
. - therascreen® EGFR Mutation Detection Kit RGQ approved in Japan, one of the leading markets for pairing diagnostics…
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), D…
. - Reallocating resources to accelerate strategic initiatives focused on driving platform success, adding content, exp…
. - Binding agreement based on terms of QIAGEN's offer in June 2011 to acquire initial stake in Ipsogen S.A. and then m…
. - Net sales of $264.3 million (0%, -2% CER) reflect anticipated soft start to 2011, disruptions in Japan and other ma…
. - Net sales of $274.3 million in line with QIAGEN's quarterly expectations, 8% organic net sales growth excluding swi…
QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Abbott (ABT: NYSE) today announced that they have entered into…